BR0215360A - Derivados de indolina úteis como inibidores de proteìna quinase - Google Patents

Derivados de indolina úteis como inibidores de proteìna quinase

Info

Publication number
BR0215360A
BR0215360A BR0215360-2A BR0215360A BR0215360A BR 0215360 A BR0215360 A BR 0215360A BR 0215360 A BR0215360 A BR 0215360A BR 0215360 A BR0215360 A BR 0215360A
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
protein kinase
indoline derivatives
derivatives useful
useful
Prior art date
Application number
BR0215360-2A
Other languages
English (en)
Inventor
John H Griffin
Roger Briesewitz
Jonathan W Wray
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of BR0215360A publication Critical patent/BR0215360A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

"DERIVADOS DE INDOLINA úTEIS COMO INIBIDORES DE PROTEìNA QUINASE". Compostos de fórmula (I) na qual R^ 1^, R^ 2^, R^ 3^ e R^ 4^ têm o significado dado na especificação, são inibidores de tirosina quinase receptora úteis no tratamento de distúrbios proliferativos, tal como câncer.
BR0215360-2A 2001-12-27 2002-12-20 Derivados de indolina úteis como inibidores de proteìna quinase BR0215360A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34374601P 2001-12-27 2001-12-27
US34381301P 2001-12-27 2001-12-27
PCT/US2002/041252 WO2003057690A1 (en) 2001-12-27 2002-12-20 Indolinone derivatives useful as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
BR0215360A true BR0215360A (pt) 2004-12-14

Family

ID=26993599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215360-2A BR0215360A (pt) 2001-12-27 2002-12-20 Derivados de indolina úteis como inibidores de proteìna quinase

Country Status (22)

Country Link
US (3) US6686362B2 (pt)
EP (1) EP1458713B1 (pt)
JP (1) JP4363985B2 (pt)
KR (1) KR100965519B1 (pt)
CN (1) CN1290844C (pt)
AT (1) ATE302771T1 (pt)
AU (1) AU2002360753B2 (pt)
BR (1) BR0215360A (pt)
CA (1) CA2470480C (pt)
CO (1) CO5611126A2 (pt)
DE (1) DE60205776T2 (pt)
DK (1) DK1458713T3 (pt)
ES (1) ES2247411T3 (pt)
HK (1) HK1068886A1 (pt)
HU (1) HUP0500111A3 (pt)
IL (1) IL162203A0 (pt)
MX (1) MXPA04006271A (pt)
NO (1) NO327550B1 (pt)
NZ (1) NZ533219A (pt)
PL (1) PL208283B1 (pt)
RU (1) RU2316554C2 (pt)
WO (1) WO2003057690A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003259713A1 (en) * 2002-08-09 2004-02-25 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
BRPI0415773A (pt) 2003-10-24 2006-12-26 Schering Ag derivados de indolinona e sua aplicação no tratamento de estados de doença tais como cáncer
EP1699477A2 (en) * 2003-12-11 2006-09-13 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
UA94719C2 (ru) 2005-10-18 2011-06-10 Янссен Фармацевтика Н.В. Применение производного имидазол-2-карбоновой кислоты для лечения или профилактики гематологической злокачественной опухоли
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
SI2021335T1 (sl) 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Heterocikliäśne spojine kot zaviralci c-fms kinaze
EP2016074B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US7928136B2 (en) 2006-09-11 2011-04-19 Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HUE045270T2 (hu) 2010-01-05 2019-12-30 Inst Nat Sante Rech Med FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
TWI523852B (zh) 2010-01-12 2016-03-01 Ａｂ科學公司 經取代之唑衍生物、含彼之組合物及其用途
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
IN2015DN00659A (pt) 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
TWI569799B (zh) 2012-09-21 2017-02-11 安羅格製藥股份有限公司 抑制組成型活性磷酸化ｆｌｔ３激酶的方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
JP2017523972A (ja) 2014-07-31 2017-08-24 アンセルム（アンスティテュト ナショナル ド ラ サンテ エ ド ラ ルシェルシュ メディカル） Ｆｌｔ３レセプターアンタゴニスト
EP3254698A1 (en) 2016-06-08 2017-12-13 Universite De Montpellier Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
US11078541B2 (en) 2016-11-02 2021-08-03 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
WO2019057649A1 (en) 2017-09-19 2019-03-28 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
TR200003514T2 (tr) 1998-05-29 2002-05-21 Sugen Inc. Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
JP2002532492A (ja) * 1998-12-17 2002-10-02 エフ．ホフマン−ラ ロシュ アーゲー サイクリン−依存性キナーゼ、特にｃｄｋ２のインヒビターとしての４−アルケニル（及びアルキニル）オキシドール
AU760964B2 (en) 1998-12-31 2003-05-22 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy
DE19924401A1 (de) 1999-05-27 2000-11-30 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6794395B1 (en) 1999-08-27 2004-09-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted indolinones, their manufacture and their use as medicaments
WO2001025238A2 (en) 1999-10-06 2001-04-12 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
DE19949209A1 (de) 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
AU2576501A (en) 1999-12-08 2001-06-18 Advanced Medicine, Inc. Protein kinase inhibitors
ME00415B (me) 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori
WO2002002551A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
ES2311023T3 (es) 2000-08-18 2009-02-01 Millennium Pharmaceuticals, Inc. Derivados de quinazolina como inhibidores de cinasa.
JP2004518669A (ja) 2000-12-20 2004-06-24 スージェン・インコーポレーテッド ４−アリール置換インドリノン
AU2003259713A1 (en) * 2002-08-09 2004-02-25 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
EP1699477A2 (en) * 2003-12-11 2006-09-13 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases

Also Published As

Publication number Publication date
NZ533219A (en) 2005-10-28
DE60205776D1 (en) 2005-09-29
NO327550B1 (no) 2009-08-10
JP2005514420A (ja) 2005-05-19
WO2003057690A1 (en) 2003-07-17
AU2002360753B2 (en) 2008-08-21
MXPA04006271A (es) 2004-10-04
CN1290844C (zh) 2006-12-20
ES2247411T3 (es) 2006-03-01
DE60205776T2 (de) 2006-06-14
US6686362B2 (en) 2004-02-03
US7223783B2 (en) 2007-05-29
DK1458713T3 (da) 2005-10-31
NO20042926L (no) 2004-07-08
IL162203A0 (en) 2005-11-20
HUP0500111A2 (hu) 2005-07-28
KR100965519B1 (ko) 2010-06-23
HUP0500111A3 (en) 2009-10-28
US20030171378A1 (en) 2003-09-11
JP4363985B2 (ja) 2009-11-11
PL369602A1 (en) 2005-05-02
CN1608063A (zh) 2005-04-20
RU2316554C2 (ru) 2008-02-10
CA2470480A1 (en) 2003-07-17
KR20040070283A (ko) 2004-08-06
RU2004122918A (ru) 2005-03-27
US7060703B2 (en) 2006-06-13
AU2002360753A1 (en) 2003-07-24
EP1458713B1 (en) 2005-08-24
PL208283B1 (pl) 2011-04-29
US20040198804A1 (en) 2004-10-07
US20060142281A1 (en) 2006-06-29
EP1458713A1 (en) 2004-09-22
CA2470480C (en) 2010-12-14
HK1068886A1 (en) 2005-05-06
CO5611126A2 (es) 2006-02-28
ATE302771T1 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
AU9102198A (en) Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
MXPA04004107A (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal.
DK1200412T3 (da) Antiproliferative imidazolforbindelser
CA2366932A1 (en) Cyclic protein tyrosine kinase inhibitors
PL406680A1 (pl) Inhibitory kinaz tyrozynowych
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
DE60333387D1 (de) Triazolopyridazine als proteinkinase-inhibitoren
ATE195734T1 (de) Aryliden-und heteroaryliden-oxindol derivate als tyrosin kinase inhibitoren
BR0209149A (pt) Ftalazinonas
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
ATE296809T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
BRPI0407841A (pt) inibidores heterocìclicos de quinase
DE60106409D1 (de) 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
MXPA04005809A (es) Inhibidores de proteinas quinasas.
ATE281439T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
UY26498A1 (es) Pirroles sustituidos
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.